Omics, Bioinformatics and Flow Cytometry Core
Omics, Bioinformatics and Flow Cytometry Core
批准号:
10630580
负责人:
MICHAEL R GARRETT
金额:
$22.41万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-07-15 至 2028-06-30
关键词:
African American populationApoptosisBioinformaticsBiologicalBiological AssayBiological ProcessCardiorenal syndromeCell CycleCell NucleusCell ProliferationCell SeparationCellsCenters of Research ExcellenceClinicalComplementConsultationsCountryData SetDiseaseEnhancement TechnologyEnsureEquipmentFacultyFaculty WorkshopFlow CytometryFundingGene ExpressionGenerationsGeneticGenomicsGoalsHealthHigh PrevalenceHistorically Black Colleges and UniversitiesImmuneInfrastructureInstitutionInstructionMaintenanceMass Spectrum AnalysisMetabolic DiseasesMethodologyMississippiMolecularMolecular AnalysisMolecular BiologyMorbidity - disease rateNamesNucleic AcidsObesityPhasePhenotypePilot ProjectsPopulationProteomicsQuality ControlResearchResearch PersonnelResearch Project GrantsResourcesScientific Advances and AccomplishmentsScientistServicesSmall RNASortingStudentsSupervisionSystems BiologyTechnical ExpertiseTechniquesTechnologyTraining and EducationUnited StatesWorkXCL1 genecell typecomplex dataepigenomegenome sequencinggenomic dataglucose uptakeimprovedinsightinstrumentinstrumentationmeetingsmortalitymultidisciplinarymultiple omicsnext generation sequencingprogramsrelease of sequestered calcium ion into cytoplasmservice deliverysingle-cell RNA sequencingtraining opportunitytranscriptometranscriptome sequencingtranscriptomicsundergraduate studentwhole genome
中文摘要
核心C-OMICS、生物信息学和流式细胞术
项目摘要/摘要
心肾和代谢性疾病研究中心(CMDRC)Cobre的目标是将
一个由基础、临床和人口科学家组成的多学科小组,共同致力于以下主题
心肾和代谢性疾病。在第一阶段和第二阶段,CMDRC-Core C提供了Cobre
调查人员和外部研究人员可以获得技术专长和设备,以执行各种任务
分子、遗传和下一代测序研究。在第一阶段和第二阶段,核心C还制作了
在确保其服务可持续性方面取得重大进展。在第三阶段,新命名的核心C-
组学、生物信息学和流式细胞术将扩展其服务,并提供尖端的细胞和
通过在第一阶段和第二阶段支持的现有基础设施上进行分子分析(基因组学和
质谱学)提供新的尖端组学方法,并通过
最近收购了最先进的细胞分选和流式细胞仪设备。全基因组学与生物信息学
分核和细胞分选/流式细胞术分核将使CMDRC调查人员能够全面
分子或系统生物学通过对细胞类型的详细了解来解决他们的研究问题
特定的功能,生成“组学”数据集,并最终与详细的表型相结合
提供更深入和深入了解与肥胖、心脏和肾脏、
和代谢性疾病。核心C有四个目标:(1)为CMDRC调查人员提供技术支持
专业知识和尖端组学服务,包括下一代测序技术(单细胞
RNA测序、空间转录),并通过利用现有的想法促进蛋白质组学技术
资助的基础设施(提供和协调蛋白质组学服务,并通过IDEA国家资源
定量蛋白质组学计划);(2)为CMDRC研究人员提供尖端细胞分类
和流式细胞仪的专业知识和服务;(3)为学生提供教育和培训机会,
受训人员,以及组学技术和流式细胞术方面的教员;以及(4)在以下方面提供持续改进
现有的分析和服务,并通过收购新的切割技术来增强技术能力
有助于核心可持续发展的边缘工具。因此,这是CMDRC的目标
-核心C,协助研究人员推进肥胖、心脏肾和代谢性疾病的科学发现
通过应用最先进的细胞分类、流式细胞仪和组学技术,产生更多
对这些疾病的洞察。除了CMDRC调查人员外,在阶段继续为Cobre提供资金
3将对提供外部研究人员产生重大影响(在密西西比州的其他本科生
机构和历史上的黑人学院和大学(HBCU))获得设备和专业知识
否则在我们国家的地区是不可用的。
英文摘要
CORE C – OMICS, BIOINFORMATICS AND FLOW CYTOMETRY CORE
PROJECT SUMMARY/ABSTRACT
The goal of the Cardiorenal and Metabolic Disease Research Center (CMDRC) COBRE is to bring together
a multidisciplinary group of basic, clinical, and population scientists to work synergistically on the theme of
cardiorenal and metabolic diseases. During Phases 1 and 2, the CMDRC - Core C provided COBRE
investigators and external researchers access to technical expertise and equipment to perform a wide variety
of molecular, genetic, and next generation sequencing studies. During Phases 1 and 2, Core C also made
major advances toward ensuring sustainability of its services. During Phase 3, the newly named Core C -
Omics, Bioinformatics and Flow Cytometry will extend its services and offer cutting-edge cellular and
molecular analysis through building on existing infrastructure supported in Phases 1 and 2 (Genomics and
Mass Spectrometry) to offer new cutting-edge omics methodologies as well as offer new capabilities through
recently acquired state-of-the-art cell sorting and flow cytometry equipment. The Omics and Bioinformatics
Sub-Core and Cell Sorting/Flow Cytometry Sub-Core will allow CMDRC investigators comprehensive
molecular or systems biology approaches to their research questions through detailed insight into cell-type
specific function, generation of “omics” datasets, and ultimately integration with detailed phenotype
information to provide greater depth and insight into biological processes associated with obesity, cardiorenal,
and metabolic diseases. Core C has four aims: (1) to provide CMDRC investigators access to technical
expertise and cutting-edge omics services, including next generation sequencing technologies (single cell
RNA sequencing, spatial transcriptomics) and facilitate proteomic technologies by leveraging existing IDeA
funded infrastructure (offer and coordinate proteomics services and through IDeA National Resource for
Quantitative Proteomics program); (2) to provide CMDRC investigators access to cutting-edge cell sorting
and flow cytometry expertise and services; (3) to provide education and training opportunities for students,
trainees, and faculty in omics technologies and flow cytometry; and (4) to provide continuous improvement in
existing assays and services and to enhance technological capabilities through acquisition of new cutting-
edge instrumentation that will assist in sustainability of the Core. Therefore, it is the objective of the CMDRC
- Core C to aid investigators in advancing scientific discovery in obesity, cardiorenal, and metabolic diseases
through application of state-of-the-art cell sorting, flow cytometry, and omics technologies to generate greater
insights into these diseases. Aside from CMDRC investigators, continued funding of the COBRE during Phase
3 will have a significant impact on providing external researchers (at other Mississippi undergraduate
institutions and Historically Black Colleges and Universities (HBCUs)) access to equipment and expertise that
would otherwise not be available in our region of the country.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Project 1 - TBD
-
批准号:10553868
-
项目类别:
-
资助金额:$21.1万
-
财政年份:2023
-
负责人:MICHAEL R GARRETT
-
依托单位:
Molecular Center of Health and Disease
-
批准号:10553864
-
项目类别:
-
资助金额:$228.38万
-
财政年份:2023
-
负责人:MICHAEL R GARRETT
-
依托单位:
Core B-Omics and Gene-Editing
-
批准号:10553866
-
项目类别:
-
资助金额:$48.28万
-
财政年份:2023
-
负责人:MICHAEL R GARRETT
-
依托单位:
Core A- Administration, Education, and Mentoring
-
批准号:10553865
-
项目类别:
-
资助金额:$56.84万
-
财政年份:2023
-
负责人:MICHAEL R GARRETT
-
依托单位:
Genetic Targets of Hypertension End Organ Damage
-
批准号:10198017
-
项目类别:
-
资助金额:$38.75万
-
财政年份:2018
-
负责人:MICHAEL R GARRETT
-
依托单位:
Genetic Targets of Hypertension End Organ Damage
-
批准号:9920359
-
项目类别:
-
资助金额:$3.35万
-
财政年份:2018
-
负责人:MICHAEL R GARRETT
-
依托单位:
Core C - Genomics, Animal Models and Advanced Phenotyping Core
-
批准号:10403631
-
项目类别:
-
资助金额:$38.62万
-
财政年份:2013
-
负责人:MICHAEL R GARRETT
-
依托单位:
Core C - Genomics, Animal Models and Advanced Phenotyping Core
-
批准号:10159921
-
项目类别:
-
资助金额:$38.62万
-
财政年份:2013
-
负责人:MICHAEL R GARRETT
-
依托单位:
Genetics of Renal End Organ Damage in Hypertension
-
批准号:8477235
-
项目类别:
-
资助金额:$35.23万
-
财政年份:2009
-
负责人:MICHAEL R GARRETT
-
依托单位:
Genetics of Renal End Organ Damage in Hypertension
-
批准号:8289584
-
项目类别:
-
资助金额:$37.0万
-
财政年份:2009
-
负责人:MICHAEL R GARRETT
-
依托单位:
Genetics of Renal End Organ Damage in Hypertension
-
批准号:8123186
-
项目类别:
-
资助金额:$37.38万
-
财政年份:2009
-
负责人:MICHAEL R GARRETT
-
依托单位:
Genetics of Renal End Organ Damage in Hypertension
-
批准号:7906923
-
项目类别:
-
资助金额:$37.25万
-
财政年份:2009
-
负责人:MICHAEL R GARRETT
-
依托单位:
Genetics of Renal End Organ Damage in Hypertension
-
批准号:7715407
-
项目类别:
-
资助金额:$38.0万
-
财政年份:2009
-
负责人:MICHAEL R GARRETT
-
依托单位:
Genetic Analysis of Renal Disease in SHR and Dahl S Rats
-
批准号:6637544
-
项目类别:
-
资助金额:$25.73万
-
财政年份:2001
-
负责人:MICHAEL R GARRETT
-
依托单位:
Core C - Genomics, Animal Models and Advanced Phenotyping Core
-
批准号:9920748
-
项目类别:
-
资助金额:$36.6万
-
财政年份:--
-
负责人:MICHAEL R GARRETT
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位:
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
-
批准号:39500043
-
项目类别:青年科学基金项目
-
资助金额:9.0万元
-
批准年份:1995
-
负责人:梁克
-
依托单位: